Impact of a Second Trump Presidency on Biotech and Healthcare

This chapter examines the potential repercussions of a second Trump administration on the healthcare system and biotech industry, particularly regarding FDA oversight and women's health. Speakers express mixed emotions and concerns about regulatory changes and the broader implications for access to healthcare and drug development. They also discuss possible positive outcomes, emphasizing the importance of evidence-based practices amidst rising anxiety in the biotech community.